A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin

Journal of the National Cancer Institute

Volumn 104, Issue 11, 2012, Pages 810-814

  Fraser, Callum G ^a   Allison, James E ^b,c   Halloran, Stephen P ^d   Young, Graeme P ^e  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DIVISION OF RESEARCH   (United States)

^d ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

BIOSENSOR; FECES ANALYSIS; HEMOGLOBIN ANALYSIS; HUMAN; IMMUNOCHEMISTRY; LABORATORY TEST; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW;

COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FECES; GUAIAC; HEMOGLOBINS; HUMANS; IMMUNOCHEMISTRY; INDICATORS AND REAGENTS; MEDICAL RECORDS; METRIC SYSTEM; OCCULT BLOOD; REFERENCE STANDARDS;

EID: 84862194722     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs190     Document Type: Review

References (34)

1. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): an update. Am J Gastroenterol. 2008; 103 (6): 1541-1549
2. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000 ; 343 (22): 1603-1607
3. Fraser CG. Faecal occult blood tests-eliminate, enhance or update? Ann Clin Biochem. 2008; 45 (2): 117-121
4. Duffy MJ, van Rossum LGM, van Turenhout ST, et al. Use of faecal markers in screening for colorectal neoplasia: a European Group on Tumor Markers (EGTM) position paper. Int J Cancer. 2011; 128 (1): 3-11
5. Segnan N, Patnick J, von Karsa L, eds. European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis. 1st edn. 2010. http ://bookshop. europa. eu/en/european-guidelines-for-quality-assurance-in- colorectal-cancer-screening-and-diagnosis-pbND3210390/. Accessed November 1, 2011
6. Lee TJW, Clifford GM, Rajasekhar P, et al. High yield of colorectal neoplasia detected by colonoscopy following a positive faecal occult blood test in the NHS Bowel Cancer Screening Programme. J Med Screen. 2011 ; 18 (2): 82-86
7. Young GP, Cole S. Which fecal occult blood test is best to screen for colorectal cancer? Nature Clin Pract Gastroenterol Hepatol. 2009; 6 (3): 140-141
8. Hoff G, Dominitz JA. Contrasting US and European approaches to colorectal cancer screening: which is best? Gut. 2010; 59 (3): 407-414
9. Allison JE. Colorectal cancer screening guidelines: the importance of evidence and transparency. Gastroenterology. 2010; 138 (5): 1648-1652
10. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007; 99 (19): 1462-1470
11. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and fl exible sigmoidoscopy. Gut. 2010; 59 (1): 62-68
12. van Rossum LG, van Rijn AF, Laheij RJ, et al. Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. Br J Cancer. 2009; 101 (8): 1274-1281
13. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008; 135 (1): 82-90
14. Allison JE, Fraser CG, Halloran SP, Young GP. Comparing FIT: improved standardization is needed now. Gastroenterology. 2012; 142 (3): 422-424
15. Fraser CG. Fecal occult blood tests. Life savers or outdated colorectal screening tools? Clin Lab News. 2011; 37 (3): 8-10
16. Fraser CG, Matthew CM, Mowat NA, Wilson JA, Carey FA, Steele RJ Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study. Lancet Oncol. 2006; 7 (2): 127-131
17. Fraser CG, Mathew CM, Mowat NA, Wilson JA, Carey FA, Steele RJ Evaluation of a card collection-based faecal immunochemical test in screening for colorectal cancer using a two-tier refl ex approach. Gut. 2007; 56 (10): 1415-1418
18. Brenner H, Haug U, Hundt S. Inter-test agreement and quantitative cross-validation of immunochromatographical fecal occult blood tests. Int J Cancer. 2010; 127 (7): 1643-1649
19. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med. 2009; 150 (3): 162-169
20. Ayling RM. New faecal tests in gastroenterology. Ann Clin Biochem. 2012; 49 (1): 44-54
21. Brenner H, Haug U, Hundt S. Sex differences in performance of fecal occult blood testing. Am J Gastroenterol. 2010; 105 (11): 2457-2464
22. Fraser CG. Screening for colorectal neoplasia with faecal tests. Lancet Oncol. 2011; 12 (6): 516-517
23. Khalid-de Bakker CA, Jonkers DM, Sanduleanu S, et al. Test performance of fecal occult blood testing and sigmoidoscopy compared with colonoscopy screening for colorectal advanced adenoma. Cancer Prev Res. 2011 ; 4 (10): 1563-1571
24. McDonald PJ, Digby J, Strachan JA, Steele RJC, Fraser CG. Faecal haemoglobin concentrations by gender and age: implications for populationbased screening for colorectal cancer. Clin Chem Lab Med. 2012; 50 (5) In press
25. Levin TR. Optimizing colorectal cancer screening by getting FIT right Gastroenterology. 2011; 141 (5): 1551-1555
26. Wilschut JA, Habbema JD, van Leerdam ME, et al. Fecal occult blood testing when colonoscopy capacity is limited. J Natl Cancer Inst. 2011 ; 103 (23): 1741-1751
27. Woo HY, Mok RS, Park YN, et al. A prospective study of a new immunochemical fecal occult blood test in Korean patients referred for colonoscopy . Clin Biochem. 2005; 38 (4): 395-399
28. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997; 32 (9): 920-924
29. White GH. Metrological traceability in clinical biochemistry. Ann Clin Biochem. 2011; 48 (5): 393-409
30. Petersen PH, Sandberg S, Fraser CG. Do new concepts for deriving permissible limits for analytical imprecision and bias have any advantages over existing consensus? Clin Chem Lab Med. 2011; 49 (4): 637-640
31. International Organization for Standardization. ISO 15189:2007. Medical Laboratories-Particular Requirements for Quality and Competence. Geneva, Switzerland: ISO; 2007
32. Grazzini G, Ventura L, Zappa M, et al. Infl uence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district. Gut. 2010; 59 (11): 1511-1515
33. US Department of Health and Human Services. Food and Drug Administration. Center for Devices and Radiological Health. Office of In Vitro Diagnostic Device Evaluation and Safety. Division of Immunology and Hematology. Guidance for Industry and FDA Staff. Review Criteria for Assessment of Qualitative Fecal Occult Blood In Vitro Diagnostic Devices Atlanta, GA: FDA; 2007
34. Clinical and Laboratory Standards Institute (CLSI). User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline EP12-A Waynne, PA: CLSI; 2008